Case 1: Nonsteroidal anti-inflammatory drugs (NSAIDs) relieve OA pain by inhibiting cyclooxygenases responsible for converting arachadonic acid into inflammation-mediating prostaglandins. However, NSAIDs can also promote sodium and fluid retention, which can increase mean arterial blood pressure as much as 5 to 6 mm Hg. The temporal relationship between the diagnosis of hypertension in DS and the initiation of naproxen suggests that naproxen is the cause. Therefore,the pharmacist should suggest it be discontinued and that DS’s blood pressure be rechecked a week after stopping naproxen.
Current American College of Rheumatology OA guidelines recommend the use of topical NSAIDs, topical capsaicin, or oral NSAIDs including COX-2 selective inhibitors after failing acetaminophen at doses greater than or equal to 3 g/day. Because of increased risks for NSAID-induced hypertension and renal failure in patients 75 years and older, the guidelines favor the use of topical over oral NSAIDs. In addition, guidelines specifically recommend against the use of intra-articular therapies and opioid analgesics for OA of the hand. Because DS did receive benefit from an oral NSAID, 2 g of diclofenac 1% gel applied to the affected area 4 times daily might be considered a reasonable alternative.
Case 2: Antibiotic selection should be based on choosing a drug with the narrowest effective spectrum and the least side effects. Fluoroquiolones are highly effective for UTIs and some experts consider them to be first-line drugs for empiric therapy. However, recent Infectious Disease Society of America (IDSA) UTI guidelines discourage their use as first-line treatment because of the potential to cause resistance and the desire to reserve fluoroquinolones for more serious infectsions.
The IDSA guidelines for acute uncomplicated cystitis suggest using nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days, TMP/SMX 160/800 mg twice daily for 3 days, or a single 3-g dose of fosfomycin trometamol as first-line treatments of an uncomplicated UTI. For empirical TMP/SMX use, local resistances of uropathogens (E coli, Klebsiella spp, Proteus spp, and Staphylococcus saprophyticus) should be less than 20%. Fluoroquinolones should be considered only if the first-line medications cannot be used. The guidelines also recognize that the choice of antibiotic should be individualized based on patient allergy and adherence, availability, cost, and patient/provider threshold for failure.
Based upon the ISDA guidelines and the resistance patterns at DW's clinic, nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days is a good empiric option.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs